NANO Aggregation Spółka z Ograniczoną Odpowiedzialnością (KRS 0000733047, NIP 5223126580) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. NANO Aggregation operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since May 22, 2018.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - NANO Aggregation
Identity
- Name
- NANO Aggregation Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 22, 2018
- Registry status as of
- February 13, 2026
- Latest entry
- February 12, 2026
- Founding act
- 24.04.2018 R.
Articles of association history (1)
- April 24, 2018: 24.04.2018 R.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- ALEJE JEROZOLIMSKIE, 198A, 7, 02-486, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - NANO Aggregation
Credibility rating
50.8 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - NANO Aggregation
Founded
May 22, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
1 year
2025
Registry entries
19
latest: February 12, 2026
Revenue
N/A
2025
Net profit
0 PLN
2025
Assets
5.0 K PLN
2025
Equity
N/A
2025
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - NANO Aggregation.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
